Kok Hoe Chan

16PUBLICATIONS
14CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targetsCancer geneticsClinical pharmacology and therapeutics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|Mar 26, 2026
Consolidation enfortumab vedotin and pembrolizumab after cisplatin induction in metastatic urothelial cancer: Outcomes of complete response and bladder preservation.

Kok Hoe Chan, Putao Cen, Tung Shu

|Oct 30, 2025
Impact of Age on Early CAR T-Cell Therapy Toxicity: A Propensity Score Matching Analysis.

Jia Yi Tan, Yong-Hao Yeo, Qi Xuan Ang

|Jul 22, 2025
SGLT2 inhibitors and cardiovascular outcomes in patients with multiple myeloma and concomitant type 2 diabetes mellitus.

Jia Yi Tan, Aravinthan Vignarajah, Yong Hao Yeo

|Oct 06, 2024
Double Hit in Clear-Cell Renal Cell Carcinoma With Germline Pathogenic ATM Mutation and Somatic VHL Mutation.

Kok Hoe Chan, Nicolas Duque Clavijo, Gustavo Ayala

|Jul 26, 2024
A multifaceted role of bisphosphonates from palliative care to anti-cancer therapy in solid tumors.

Sindhusha Veeraballi, Sai Samyuktha Bandaru, Chrystina Kiwan

|May 28, 2024
Complete Pathologic Response With Pembrolizumab and Enfortumab Vedotin in Urothelial Carcinoma of the Upper Urinary Tract.

Kok Hoe Chan, Tung Shu, Majd Al Shaarani

Pageof 3

Frequent Collaborators

2 joint publications

Sindhusha Veeraballi

2 joint publications

Hamid Shaaban

2 joint publications

Jia Yi Tan

2 joint publications

Yong-Hao Yeo